Don’t believe drug companies: 340B is a program worth saving ...Middle East

The Hill - News
Don’t believe drug companies: 340B is a program worth saving
Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms apply a familiar formula. First, start with presenting drug company-funded research as if it is non-biased. Next, use misleading statistics to accuse safety-net providers of abusing the program. After that, offer faux concerns about wanting to protect medically underserved patients. Then go even further: Blame nonprofits for the 340B savings siphoned off by pharmacy benefit managers. Finish it all off by sprinkling in quotes from activists who have direct relationships with drug compani

Hence then, the article about don t believe drug companies 340b is a program worth saving was published today ( ) and is available on The Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Don’t believe drug companies: 340B is a program worth saving )

Apple Storegoogle play

Last updated :

Also on site :



Latest News